Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 11/2018

Open Access 01-11-2018 | Original Contributions

Metabolic Surgery for the Treatment of Diabetes Mellitus Positioning of Leading Medical Associations in Mexico

Authors: Miguel F. Herrera, Eduardo García-García, Juan F. Arellano-Ramos, Miguel Agustín Madero, Jorge Antonio Aldrete-Velasco, Juan Antonio López Corvalá

Published in: Obesity Surgery | Issue 11/2018

Login to get access

Abstract

Introduction

Metabolic surgery (MS) can be a useful therapeutic strategy in patients with type 2 diabetes (DM2) and obesity.

Objective

To define the place of MS within DM2 treatment in Mexico.

Methods

A committee of experts consisting of internists and surgeons representing the leading Mexican associations involved in the field was created. Each one responded to a specific question regarding mechanisms involved in controlling DM2, surgical procedures, and the indications and contraindications for MS. This document was prepared based on the presentation and discussion of such answers.

Results

Obesity through insulin resistance, incretins, bile salts, and intestinal microbiota plays a determining role in the appearance of DM2. MS improves glucose homeostasis by reducing weight and intake, increasing incretins, and modifying bile salts and microbiota. MS leads to remission of DM2 and reduces cardiovascular risk factors in well-selected cases. We recommend MS as a therapeutic option in DM2 and grade III obesity regardless of metabolic control and grade II and grade I obesity with poor glycemic control. MS could be considered an option in grade II obesity with good metabolic control in the presence of associated comorbidities. Gastric bypass presents the most favorable risk-benefit profile.

Conclusions

Current evidence endorses the inclusion of MS in the algorithm for treatment of DM2 and obesity. The therapeutic approach must be multidisciplinary at experienced centers.
Literature
1.
Rubino F, Nathan DM, Eckel RH, et al. On behalf of the delegates of the 2nd diabetes surgery summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77.CrossRefPubMed
2.
Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150:2518–25.CrossRefPubMed
3.
Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Mechanisms of improved glycemic control after Roux-en-Y gastric bypass. Diabetology. 2012;55:1890–901.CrossRef
4.
Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and body weight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2:152–64.CrossRefPubMed
5.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.CrossRefPubMed
6.
American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In standards of medical care in diabetes 2016. Diabetes Care. 2016;39(Suppl. 1):S13–22.
7.
Alberti KG, Eckel RH, Grundy MS, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed
8.
9.
Brethauer SA, Kim J, el Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11:489–506.CrossRefPubMed
10.
Abdullah A, Peeters A, de Courten M, et al. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diab Res Clin Pract. 2010;89:309–19.CrossRef
11.
Kodama S, Horikawa C, Fijihara K, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obesity Rev. 2014;15:202–14.CrossRef
12.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMed
13.
14.
Triplitt C. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. 2006;26:360–74.CrossRefPubMed
15.
Pastors JG, Warshaw H, Daly A, et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002;25:608–13.CrossRefPubMed
16.
Wadden TA. The evolution of very-low-calorie diets: an update and metaanalysis. Obesity (Silver Spring). 2006;14:1283–93.CrossRef
17.
Feinman RD, Pogozelsky WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015;31:1–13.CrossRefPubMed
18.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.CrossRefPubMed
19.
20.
Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999;34:1975–81.CrossRefPubMed
21.
Hwang I, Park YJ, Kim YR, et al. Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB J. 2015;29:2397–411.CrossRefPubMed
22.
Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–6.CrossRefPubMed
23.
Sweeney TE, Morton M. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature. Best Pract Res Clin Gastroenterol. 2014;28:727–40.CrossRefPubMedPubMedCentral
24.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014;370:2002–13.CrossRefPubMedPubMedCentral
25.
Olivarius N d F, Beck-Nielsen H, Andreasen AH, et al. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ. 2001;323:970–5.CrossRefPubMedPubMedCentral
26.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
27.
Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRefPubMed
28.
Rubino F. From bariatric to metabolic surgery: definition of a new discipline and implications for clinical practice. Curr Atheroscler Rep. 2013;15:369.CrossRefPubMed
29.
Chang SH, Stoll CRT, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149:275–87.CrossRefPubMedPubMedCentral
30.
Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8(8):CD003641.
31.
Aminian A, Brethauer SA, Kirwan JP, et al. How safe is metabolic/diabetes surgery? Diabetes Obes Metab. 2015;17:198–201.CrossRefPubMed
32.
Kim JH, Wolf B. Bariatric/metabolic surgery. Short- and long-term safety. Curr Atheroscler Rep. 2012;14:597–605.CrossRefPubMed
33.
Montravers P, Augustin P, Zappella N, et al. Diagnosis and management of the postoperative surgical and medical complications of bariatric surgery. Anaesth Clin Care Pain Med. 2015;34:45–52.CrossRef
34.
Nguyen NT, Rivera R, Wolfe BM. Factors associated with operative outcomes in laparoscopic gastric bypass. J Am Coll Surg. 2003;197(4):548–55.CrossRefPubMed
35.
Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.CrossRefPubMed
36.
Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annual Rev Med. 2010;61:393–411.CrossRef
37.
Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes. 2013;37:1553–9.CrossRef
38.
Miras AD, le Roux CW. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2013;10:575–84.CrossRefPubMed
39.
Tremaroli V, Karlsson F, Werling M, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 2015;22:228–38.CrossRefPubMedPubMedCentral
40.
Nosso G, Griffo E, Cotugno M, et al. Comparative effects of Roux-en-Y gastric bypass and sleeve gastrectomy on glucose homeostasis and incretin hormones in obese type 2 diabetic patients: a one-year prospective study. Horm Metab Res. 2016;48:312–7.CrossRefPubMed
41.
42.
Biertho L, Lebel S, Marceau S, et al. Biliopancreatic diversion with duodenal switch: surgical technique and perioperative care. Surg Clin North Am. 2016;96:815–26.CrossRefPubMed
43.
Harvey EJ, Arroyo K, Komer J, et al. Hormone changes affecting energy homeostasis after metabolic surgery. Mt Sinai J Med. 2010;77:446–65.CrossRefPubMed
44.
Mingrone G, Nolfe G, Gissey GC, et al. Circadian rhythms of GYP and GLP-1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetology. 2009;52:873–81.CrossRef
45.
Finelli C, Padula MC, Martelli G, et al. Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? World J Gasteroenterol. 2014;20:16649–64.CrossRef
46.
47.
Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs. sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146:143–8.CrossRefPubMed
48.
Li JF, Lai DD, Ni B, et al. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg. 2013;56:E158–64.CrossRefPubMedPubMedCentral
49.
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5-year follow-up of an open-label, single centre, randomized controlled trial. Lancet. 2015;386:964–73.CrossRefPubMed
50.
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.CrossRefPubMed
51.
Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocr Pract. 2013;19:337–72.CrossRefPubMedPubMedCentral
52.
Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRefPubMed
53.
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.CrossRefPubMed
54.
Baskota A, Li S, Dhakal N, et al. Bariatric surgery for type 2 DM in patients with BMI < 30 kg/m2: a systematic review and meta-analysis. PLoS One. 2015;10:e0132335.CrossRefPubMedPubMedCentral
55.
Chen Y, Corsino L, Shantavasinkul PC, et al. Gastric bypass surgery leads to long-term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications. Ann Surg. 2016;263:1138–42.CrossRefPubMed
56.
Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol. 2014;2:38–45.CrossRefPubMedPubMedCentral
57.
Lee WJ, Hur K, Lakadawala M, et al. Predicting the success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379–84.CrossRefPubMed
58.
Lee WJ, Chong K, Chen SC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26:2418–24.CrossRefPubMed
59.
Yan J, Cohen R, Aminian A. Reoperative bariatric surgery for treatment of type 2 diabetes mellitus. Surg Obes Relat Dis. 2017;13:1412–21.CrossRefPubMed
Metadata
Title
Metabolic Surgery for the Treatment of Diabetes Mellitus Positioning of Leading Medical Associations in Mexico
Authors
Miguel F. Herrera
Eduardo García-García
Juan F. Arellano-Ramos
Miguel Agustín Madero
Jorge Antonio Aldrete-Velasco
Juan Antonio López Corvalá
Publication date
01-11-2018
Publisher
Springer US
Published in
Obesity Surgery / Issue 11/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3357-y

Other articles of this Issue 11/2018

Obesity Surgery 11/2018 Go to the issue

Original Contributions

Evidence That the Length of Bile Loop Determines Serum Bile Acid Concentration and Glycemic Control After Bariatric Surgery

Letter to Editor/LED Reply

Reply to: Yet Another Mortality with a Bilio-Pancreatic Limb of > 200 cm with One Anastomosis Gastric Bypass

Review Article

Does Bariatric Surgery Cause Vitamin A, B1, C or E Deficiency? A Systematic Review

Original Contributions

Laparoscopic Sleeve Gastrectomy Is Associated with Lower 30-Day Morbidity Versus Laparoscopic Gastric Bypass: an Analysis of the American College of Surgeons NSQIP

Original Contributions

Calibration of the Gastric Pouch in Laparoscopic Roux-en-Y Gastric Bypass: Does It Matter? The Influence on Weight Loss

Original Contributions

Influence of Time Interval from Bariatric Surgery to Conception on Pregnancy and Perinatal Outcomes